Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Keratosis, Actinic 2Hemangioma 2Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Melanoma 1Insulinoma 1Hyperinsulinism 1Hematologic Neoplasms 1Congenital Hyperinsulinism 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × Solutions × Clear all
NCT05952804 2026-04-21

IVIG for Infection Prevention After CAR-T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 2 Recruiting
150 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡